

# UNIVERSITY OF BIRMINGHAM

## Research at Birmingham

### Frailty and the Immune System

Drew, William; Wilson, Daisy; Sapey, Elizabeth

*DOI:*

[10.14302/issn.2474-7785.jarh-17-1578](https://doi.org/10.14302/issn.2474-7785.jarh-17-1578)

*License:*

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Drew, W, Wilson, D & Sapey, E 2017, 'Frailty and the Immune System', *Journal of Ageing Research and Healthcare*, vol. 2, no. 1, pp. 1-14. <https://doi.org/10.14302/issn.2474-7785.jarh-17-1578>

[Link to publication on Research at Birmingham portal](#)

#### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

#### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Frailty and the immune system

William Drew<sup>1</sup>, Daisy Wilson<sup>1</sup>, Elizabeth Sapey<sup>1</sup>

1. Institute of Ageing and Inflammation, University of Birmingham, Edgbaston, Birmingham, UK, B15 2GW

### Abstract

Frailty describes a medical syndrome that confers increased vulnerability to disproportionate changes in health status following minor stressors. With loss of homeostatic reserve in multiple physiological systems, frailty conveys an increased risk of adverse health outcomes. Despite the lack of a clear universal definition, the utilisation of two landmark operational models has allowed a rapid expansion in frailty-centred research.

The pathophysiology of frailty is yet to be elucidated in the literature, but a critical role for a heightened inflammatory state is hypothesised. Raised levels of pro-inflammatory cytokines are associated with frailty, with emerging evidence relating their biochemical action with development of the frailty phenotype. Dysregulation of both the innate and adaptive immune system are key components of the frailty syndrome. Remodelling of the T cell compartment and upregulated inflammatory pathways are theorised to propagate the heightened inflammatory state critical in the frailty syndrome. Increased neutrophil counts, in conjunction with ineffective neutrophil migration associated with age, is theorised to produce tissue damage and secondary inflammation conducive of the inflammatory picture in frailty.

Beyond the gold standard of the comprehensive geriatric assessment, management of frailty is a fast-evolving area of research. Exercise interventions have shown promising results, improving functional ability and showing beneficial immunomodulation. Vitamin D supplementation, with proposed anti-inflammatory effects, nutritional support and pharmacological treatments all provide promising areas for future therapeutic intervention.

**Corresponding Author :** Institute of Ageing and Inflammation, University of Birmingham, Edgbaston, Birmingham, UK, B15 2GW. [d.v.wilson@bham.ac.uk](mailto:d.v.wilson@bham.ac.uk)

**Running title :** Frailty and immunity

**Key words :** Frailty; Immune System; Inflammation; Immunesenescence

**Received** May 05, 2017

**Accepted** May 21, 2017

**Published** Jun 02, 2017

## Frailty and the Frail Immune System

Frailty is a syndrome characterised by the loss of homeostatic reserve in multiple physiological systems. It is a serious issue for an increasingly elderly population that is associated with increased vulnerability to dramatic health changes in response to often minor stressor events <sup>(1)</sup>. Described as the most problematic consequence of population ageing <sup>(2)</sup>, frailty conveys an increased risk of adverse outcomes, including falls, disability and mortality. The resultant burden on both health and social care systems globally is only set to increase in an internationally ageing population <sup>(3, 4)</sup>. Now recognised as a clinical syndrome disparate from disability and comorbidity <sup>(5)</sup>, the importance of identifying and introducing effective management for patients with frailty is becoming increasingly evident.

### Defining Frailty

The term “frailty” has been used previously to describe a whole host of conditions, ranging from general debility, bone weakness to cognitive impairment <sup>(6, 7)</sup>. However, over the last 20 years, frailty as a concept has evolved to be defined as a distinct clinical syndrome, widely recognised as a vital diagnosis due to its association with poorer clinical outcomes and increased health care utilisation. Despite this, there is

still no universal consensus for the classification of frailty as a syndrome. Currently, there are two widely accepted operational definitions: the frailty phenotype model and the frailty index model, compared in Table 1.

The phenotype model, more widely utilised in research <sup>(8)</sup>, was pioneered by Fried <sup>(9)</sup>. It states that frailty can be thought of as a clinical phenotype incorporating five features: shrinking (unintentional weight loss), poor endurance and energy (self-reported exhaustion), low physical activity level (low energy expenditure), slowness (slow gait speed) and weakness (weak grip strength) <sup>(9)</sup>. Individuals with three or more of these features were classified as frail, one or two features as pre-frail. Frailty classified in this way was shown to correlate with an increased risk of adverse outcomes, including falls, mobility and function, hospitalisation and death <sup>(9)</sup>. This association was shown to hold true in different and more diverse cohorts such as a Chinese cohort <sup>(10)</sup>.

The frailty index model was pioneered by Rockwood and describes frailty as the cumulative effect of individual deficits <sup>(11)</sup>. Patients with more deficits were more likely to be frail <sup>(11)</sup> and were at an increased risk of adverse outcomes including mortality <sup>(12, 13)</sup>. Deficits were classified as 92 variables, originally identified to classify health status in the elderly <sup>(14)</sup>. These variables

**Table 1 – The Frailty Phenotype and Frailty Index operational models of the frailty syndrome.**

With the lack of a single unifying definition, these two operational models provide the definitions of frailty used in research and clinical practice. The frailty phenotype model identifies an individual as frail by the presence of three of the five symptoms shown above. An individual is classed as pre-frail if they exhibit one or two of the symptoms. The frailty index model classifies an individual as frail if their number of deficits, as a proportion of the total deficits assessed, is greater than 0.2. Deficits can include any variable that is associated with ill health, increases in prevalence with age but does not saturate ( $\geq 1\%$ ) at old age.

The Frailty Phenotype Model Fried <sup>(9)</sup>	The Frailty Index Model Rockwood <sup>(14)</sup>
3/5 of the following: <ul style="list-style-type: none"> <li>• Weight loss</li> <li>• Self-reported Exhaustion</li> <li>• Low physical Activity</li> <li>• Slowness</li> <li>• Weakness</li> </ul>	Deficit accumulation of $>0.2$ of total assessed deficits (minimum 30) Deficits can include any variable that fulfils the following criteria: <ul style="list-style-type: none"> <li>• Associated with adverse health outcomes</li> <li>• Increased in prevalence with age</li> <li>• Prevalence <math>\geq 1\%</math> (but not saturated) in old age</li> </ul>

include symptoms and signs, functional impairments and laboratory abnormalities covering a wide range of domains such as social, psychological and medical. The frailty index itself is calculated as the presence (score of 1) or absence (score of 0) of each variable as a proportion of the total. An index above 0.2 is classified as frail. At an index of 0.65, the deficit accumulation is not sustainable with life <sup>(15)</sup>. This model of frailty produces a gradation between frailty and good health. It recognises that frailty is not just a phenomenon that is present or absent, but usually presents as a gradual decline into increasing frailty. The frailty index is seen as mathematically attractive, with a distribution similar to that seen in systems with in-built redundancy <sup>(2)</sup>. This supports the theory of an accumulation of deficits leading to reduced homeostatic reserve, resulting in the vulnerability which is fundamental to the frailty syndrome <sup>(2)</sup>. Rockwood's theory has since been refined to a more manageable 30 variables, without losing validity in different data sets <sup>(16)</sup>.

Despite the two vastly different approaches to characterising frailty, both approaches show statistical convergence<sup>(17)</sup>. Although each model has their advantages; the Frailty index can identify risk of adverse outcomes from intermediate frailty more specifically and lead to more targeted treatments <sup>(17)</sup>. The two models are distinct but complimentary, with their combined/ sequential use encouraged <sup>(18)</sup>.

Frailty, co-morbidity and disability are three inter-related clinical entities, which only recently were proven to be distinct. Recent research has shown that there is consistently a population of frail individuals without co-morbidities or disability <sup>(5, 19, 20)</sup>. Despite this, the conditions overlap extensively, as a result of causal relationships between the three. Frailty often precedes disability <sup>(21)</sup>, whilst disability and co-morbidity can contribute to the development of frailty <sup>(5)</sup>.

Reports on the prevalence of frailty vary from study to study due to a lack of a universal, corroborated

definition of frailty. A systematic review of 21 studies yielded a weighted average prevalence of 10.7% in community dwelling older adults (aged 65 and older) <sup>(22)</sup>. However, this review was subject to a wide variation in reporting, resulting in huge disparity in prevalence estimates between the included primary studies. What was clear however, was the close association with age, with around a quarter of individuals over the age of 85 classified as frail <sup>(22)</sup>. There was also a clear association with gender, frailty being more prevalent in women that is independent of age <sup>(22)</sup>.

### Pathophysiology

Despite continued research efforts, the clear pathogenesis of frailty is still yet to be elucidated. Principally, the pathogenesis and progression of frailty is associated with accelerated accumulation of cellular and molecular damage in multiple bodily systems. This damage occurs naturally in normal ageing <sup>(23)</sup>, and most body systems have in built redundancy (or physiological reserve) which can account for decline in age or disease <sup>(24)</sup>. However, there is a threshold of damage, beyond which impaired body system function becomes evident. Frailty manifests in an individual who has crossed the threshold of damage in multiple physiological systems <sup>(25)</sup>. Importantly, the number of body systems affected, rather than the amount of damage in one system, is the strongest predictor of frailty <sup>(25)</sup>.

The main three systems focused upon in frailty-centred research are the immune system, endocrine system and nervous system <sup>(6)</sup>. However, changes in multiple body systems have documented impacts on the frailty syndrome including: the renal system <sup>(26)</sup>, the cardiovascular system <sup>(27, 28)</sup>, the haematological system <sup>(28, 29)</sup> and the respiratory system <sup>(30)</sup>.

There are a number of associated factors that potentially contribute to the pathogenesis of frailty, but these are sparsely illustrated and without a significant evidence base in the literature. We can postulate that chronic low-level inflammation has a key

pathophysiological role <sup>(31, 32)</sup>, as the inflammatory markers IL-6, TNF $\alpha$  and CRP, are elevated in frailty <sup>(33-35)</sup>. There is also a direct association between frailty and an increased total white blood cell count at baseline <sup>(35)</sup>, a routine clinical indicator for systemic inflammation <sup>(36)</sup>. This chronic inflammation has both indirect and direct contribution to the pathophysiology of frailty. IL-6 and TNF $\alpha$  themselves show association with the loss of muscle mass strength in frailty <sup>(37)</sup>. Inflammation has detrimental indirect effects on intermediary systems including decreased haemoglobin concentrations <sup>(38)</sup>, insulin-like Growth Factor (IGF) levels <sup>(39)</sup> and micronutrient concentrations <sup>(40)</sup>. These effects reduce the physiological reserve of the affected bodily systems, contributing to the development of frailty.

Sarcopenia is the loss of skeletal muscle mass, strength and function <sup>(41)</sup>, which occurs age. With weakness and slowness comprising a key part of the frailty phenotype, sarcopenia and frailty are understandably very closely linked. Many even describe sarcopenia as 'physical frailty'. However, we can hypothesize that sarcopenia is not only a component of frailty but it can actively cause or encourage the progression of frailty. Sarcopenia itself is associated with a chronic low level inflammatory state driven by oxidative stress and inflammatory cytokines, with raised levels of IL-6, TNF $\alpha$  and CRP, all considered key in the condition's pathogenesis <sup>(42, 43)</sup>. The development of sarcopenia can lead to a cycle of reduced physical activity, under nutrition and further inflammation that is extremely difficult to break <sup>(44, 45)</sup>. These factors have all been implicated in the pathophysiology of frailty suggesting a causative role for sarcopenia. The endocrine system is also believed to be fundamental in the pathogenesis of sarcopenia and consequently frailty. The decrease of oestrogen or testosterone in old age <sup>(36)</sup> and reduced levels of IGF-1 in frail individuals <sup>(46)</sup> can result in sarcopenia. The close relationship between sarcopenia and frailty has been postulated to extend to

the molecular level, with the dysregulation of the PI3K-Akt signalling proposed to play a role in the pathophysiology of both processes <sup>(47)</sup>.

### The Frail Immune System

The chronic pro-inflammatory state associated with frailty <sup>(31-35)</sup> is accompanied by dysregulation in both the adaptive and innate immune systems <sup>(32)</sup>. Whether these changes are cause or consequence of frailty is the topic of ongoing research and not yet elucidated in the literature.

As stated above, there is an association between frailty and raised levels of IL-6 and TNF- $\alpha$  <sup>(33-35)</sup>, as part of the heightened inflammatory state accompanying the syndrome. These inflammatory cytokines play a crucial role in the pathogenesis and propagation of the frailty syndrome. IL-6 can cause muscle degradation in a number of ways: directly by action of the proteasome <sup>(48)</sup>, through induction of insulin resistance <sup>(49)</sup> resulting in suppression of skeletal muscle hypertrophic Akt-mTOR activity <sup>(47, 50)</sup> and also through the induction of 11 $\beta$ HSD1 <sup>(51)</sup> which synthesises the catabolic molecule cortisol <sup>(52)</sup>. These processes are evident in human epidemiological studies which have shown that higher levels of IL-6 are predictive of both sarcopenia <sup>(53)</sup> and relevant frailty associated adverse health outcomes <sup>(54)</sup>. TNF $\alpha$  can directly induce skeletal muscle wasting <sup>(55)</sup>. This is especially relevant as TNF $\alpha$  levels in the skeletal muscles of frail older adults were shown to be elevated when compared to healthy younger individuals <sup>(56)</sup>. With regards to the impact of anti-inflammatory cytokines, there is a lack of evidence regarding an association between human frailty and IL-10. However, we can hypothesise that the molecule is involved in the syndrome's pathogenesis and maintenance, with murine models of frailty utilising an IL-10 knockout model <sup>(57)</sup>.

Evidence is emerging that the T cell compartment of the adaptive immune system undergoes remodelling in frailty syndrome. Age matched female

patients who were frail have been shown to have significantly more CD8+CD28- and CD8+ T cells than non-frail women <sup>(58)</sup>. Furthermore, dysregulation of CD4 T cells has been shown to be predictive of a frailty-related phenotype in HIV infected men <sup>(59)</sup>. These findings suggest that T cell dysregulation may well be associated in the frailty syndrome. This is reinforced by the finding that frail individuals have increased counts of T cells expressing chemokine CC receptor 5, representing an increase in a pro-inflammatory T-cell subset in frail older adults <sup>(60)</sup> perhaps contributing to the chronic inflammation in frailty. Further studies of the quantity, character and function of T cells in frail individuals are needed. Information regarding B cell function in frailty is extremely limited. There is emerging evidence that individuals with frailty have an impaired response to vaccination, but it is unclear whether this is secondary to the previously described T cell dysregulation or dysfunction in the B cell itself <sup>(32)</sup>.

The innate immune system of frail individuals exhibits increased cellular and molecular inflammatory markers <sup>(32)</sup>. Increased IL-6 production by peripheral blood mononuclear cells (PBMCs) <sup>(61, 62)</sup> and elevated white blood cell count are both associated with frailty <sup>(35, 63)</sup>. We can postulate that these factors are crucial in the maintenance of the heightened inflammatory state seen in frailty. There is also evidence to show an upregulation of the CXCL10 gene in the monocytes of individuals with frailty <sup>(64)</sup>, as well as upregulation of other inflammatory pathway genes <sup>(65)</sup>, further potential causes of the heightened inflammatory state in frail older adults. An association between oxidative stress, cellular senescence and frailty has been proposed, following the observation of increased expression of hydrogen peroxide-induced clone 5 (a protein that responds to oxidative stress and is key in cellular senescence) in monocytes of a frail individual <sup>(32)</sup>.

Systemic neutrophil and monocyte counts have been shown to be raised in frailty <sup>(63)</sup>. However, neutrophil chemotactic ability declines with age <sup>(66, 67)</sup> as does the ability of neutrophils to phagocytose bacteria <sup>(68)</sup> or produce extracellular traps <sup>(69)</sup>. Neutrophils, although crucial in bacterial clearance and tissue repair, can cause tissue damage as evidenced by the attenuation of muscle injury elicited on leukocyte depletion <sup>(70-72)</sup>. Thus, in frailty we can postulate that an increased number of neutrophils, migrating inefficiently, and with reduced capacity to effectively clear bacteria might cause tissue damage and produce systemic inflammation <sup>(66, 67)</sup>, potentially providing significant input to the heightened inflammatory state and muscle damage seen in frailty.

### Management of Frailty

According to the British Geriatrics Society, a Comprehensive Geriatric Assessment (CGA) reflects the gold standard of care for patients with frailty <sup>(73)</sup>. Frail patients admitted to hospital who received a CGA were more likely to return to their homes, less likely to suffer deterioration or death and showed improved cognition <sup>(74)</sup>. The key components, first described by Rubenstein <sup>(75)</sup>, are: co-ordinated multidisciplinary assessment, geriatric medicine expertise, identification of medical, physical, social and psychological problems and the formation of a care plan <sup>(74)</sup>. The main limitation of the CGA is its resource intensive nature which can restrict its incorporation into practice.


As far as interventions to prevent or reverse frailty itself, there is currently limited available research. Therefore, to improve our understanding we have also considered studies have been conducted in populations that, although not explicitly categorised as frail, may well have been frail at the time of data collection. Exercise interventions of various types have shown promising results in the literature. Systematic reviews on the topic suggest that exercise may improve functional ability and decrease disability <sup>(76, 77)</sup> in moderately frail

individuals, but not in the severely frail <sup>(76)</sup>. In these reviews, exercise was defined as activity requiring physical effort that is intended to improve or maintain fitness <sup>(76, 77)</sup>. The review conducted by Clegg et al <sup>(76)</sup> focused on home-based resistance exercise interventions, whereas the review conducted by Theou et al <sup>(77)</sup> encompassed both resistance and multicomponent interventions. The effects of resistance exercise in particular seem promising in clinical trials, reducing physical decline <sup>(78)</sup> and counteracting the weakness associated with physical frailty <sup>(79)</sup>. There is a growing body of evidence for the use of exercise to reduce the chronic low level inflammation critical in frailty <sup>(42, 80)</sup>. Resistance exercise in particular has been shown to modulate the immune system in frail older adults, reducing TNF $\alpha$  levels in skeletal muscle and permitting increased muscle protein synthesis <sup>(56)</sup>. A Cochrane review of patients in long-term residential care, who are likely to be frail, suggests that physical rehabilitation can reduce disability and improve physical condition <sup>(81)</sup>. This was supported by a separate meta-analysis that found that mobility and physical functioning was improved with physical exercise therapy in an older population with mobility issues <sup>(82)</sup>. However, an update of the Cochrane review highlighted the difficulty of drawing valid conclusions using meta-analysis from such varied datasets and interventions but did suggest that individual studies have demonstrated benefit to health status with physical activity <sup>(83)</sup>. The effect of exercise on the quality of life remains uncertain, with no conclusive evidence on the subject <sup>(76, 82)</sup>. High-intensity exercise seems to be the most effective when compared to low intensity exercise <sup>(79, 82)</sup>, but there was insufficient evidence to make a strong recommendation <sup>(77)</sup>.

Another potential treatment for frailty is nutritional and hormonal support. Caloric and protein support as well as Vitamin D replacement are both listed in the Frailty Consensus from 2013 <sup>(84)</sup> as potential

therapies for physical frailty. Protein supplementation has been shown to improve grip strength and reduce weight loss <sup>(85)</sup>. Protein supplementation has also been shown to improve physical performance in frail elderly volunteers <sup>(86)</sup>, especially when combined with resistance exercise <sup>(87, 88)</sup>. A reduced Vitamin D level has shown strong associations with both prevalent and incident physical frailty after adjusting for common confounders <sup>(89)</sup>. Vitamin D supplementation can reduce the risk of falls <sup>(90)</sup>, improve strength <sup>(91)</sup> and reduce mortality <sup>(92)</sup> in older patients. However, it is worth noting that there is conflicting evidence regarding the benefit of vitamin D supplementation, with recent research suggesting that high dose supplementation can increase the risk of falls in older adults <sup>(93)</sup>. This disparity in the literature on vitamin D supplementation may be due to inexpert targeting of the treatment and once the mechanism of action is better understood, studies may be able to show increased benefit. Recent research efforts have explored the immunomodulatory effects of vitamin D and its potential use in the treatment of inflammatory diseases <sup>(94-97)</sup>. The anti-inflammatory effect of vitamin D on human immune cells is well documented, with reduced production of pro-inflammatory cytokines <sup>(98, 99)</sup>. With the effect of vitamin D supplementation on inflammation currently being investigated <sup>(100)</sup>, we can hypothesise that vitamin D supplementation could produce beneficial modulation of the frail immune system. Despite the lack of large-scale trials assessing the efficacy of vitamin D supplementation at preventing frailty directly, the limited evidence for immune modulation in a frail population and the conflicting evidence for its use in fall prevention, it provides a promising area of research for therapeutic intervention.

No substantial body of research supports other pharmacological treatments for frailty. It has been suggested that Angiotensin Converting Enzyme inhibitors (ACEi) can improve muscle structure <sup>(101)</sup> and prevent the decline in muscle strength <sup>(102)</sup>. The LACE



**Figure 1 – The theorised influence of a heightened inflammatory state on the pathogenesis of the frailty syndrome.**

The chronic pro-inflammatory state manifest in frailty can lead directly or indirectly to the development of frailty and consequently the associated adverse health outcomes (depicted in red). This inflammatory picture can affect intermediary systems; sarcopenia and the decline of the musculoskeletal system associated with frailty pathogenesis. The remodelling of both the innate and adaptive immune systems associated with the frailty syndrome plays a key role, but whether this is cause or consequence is yet to be decided. Promising management options (depicted in blue) are emerging in the literature, providing beneficial immunomodulation and improving functional outcomes.

Trial <sup>(103)</sup>, which is currently ongoing, is set to examine whether ACEi can be used to treat sarcopenia. However, this has not been examined in frailty or in enough details to make recommendations for clinical practice. ACEi have also been shown to produce anti-inflammatory effects in multiple patient groups <sup>(104, 105)</sup>. Whether the anti-inflammatory effects of ACEi would prove beneficial in reducing the heightened inflammatory state present in frailty will need further investigation. Testosterone can improve strength, but carries with it significant risk of cardiovascular adverse events <sup>(106)</sup>. IGF-1 administration affects skeletal muscle

directly but has no proven effect on muscle strength <sup>(107)</sup>.

Figure 1 provides a summation of factors that have been implicated in the pathogenesis of frailty and therapeutic strategies that might improve patient outcomes.

### Conclusion

Frailty is a medical syndrome with increasing importance in global health care. Associated with an increased risk of adverse outcomes in older adults, its identification and appropriate management is essential for effective patient care. Continued research efforts will further our knowledge regarding the syndrome's



complex pathophysiology and potential for curative management and therapeutics strategies. The immune system is hypothesised to have a key role in the pathogenesis of frailty, with significant changes observed in the immune systems of individuals with frailty. However, whether these changes are cause or consequence will be the subject of further research.

### Acknowledgments

William Drew would like to express his gratitude to the Arthur Thomson Trust for financial support in the form of an Intercalation Bursary. Daisy Wilson is supported by a clinical research fellowship funded by the MRC-Arthritis Research UK Centre for Musculoskeletal Ageing Research. Elizabeth Sapey is funded by the Medical Research Council.

### References

1. Society TBG. Fit for Frailty - consensus best practice guidance for the care of older people living in community and outpatient settings - a report from the British Geriatrics Society. The Silver Book 2014.
2. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet*. 2013;381(9868):752-62.
3. Preparing for an Aging World: The Case for Cross-National Research. Washington DC: National Academy of Sciences.; 2001.
4. Phillips KKaDR. Global Aging: The Challenge of Success. *Population Bulletin*. 2005;60(1).
5. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. *J Gerontol A Biol Sci Med Sci*. 2004;59(3):255-63.
6. Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. *J Am Geriatr Soc*. 2006;54(6):991-1001.
7. Lally F, Crome P. Understanding frailty. *Postgrad Med J*. 2007;83(975):16-20.
8. Bouillon K, Kivimaki M, Hamer M, Sabia S, Fransson EI, Singh-Manoux A, et al. Measures of frailty in population-based studies: an overview. *BMC Geriatr*. 2013;13:64.
9. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56(3):M146-56.
10. Bandeen-Roche K, Xue QL, Ferrucci L, Walston J, Guralnik JM, Chaves P, et al. Phenotype of frailty: characterization in the women's health and aging studies. *J Gerontol A Biol Sci Med Sci*. 2006;61(3):262-6.
11. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. *J Gerontol A Biol Sci Med Sci*. 2007;62(7):722-7.
12. Rockwood K, Mitnitski A, Song X, Steen B, Skoog I. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. *J Am Geriatr Soc*. 2006;54(6):975-9.
13. Mitnitski A, Song X, Skoog I, Broe GA, Cox JL, Grunfeld E, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. *J Am Geriatr Soc*. 2005;53(12):2184-9.
14. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. *ScientificWorldJournal*. 2001;1:323-36.
15. Rockwood K, Mitnitski A. Limits to deficit accumulation in elderly people. *Mech Ageing Dev*. 2006;127(5):494-6.
16. Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. *J Am Geriatr Soc*. 2010;58(4):681-7.

17. Rockwood K, Andrew M, Mitnitski A. A comparison of two approaches to measuring frailty in elderly people. *J Gerontol A Biol Sci Med Sci.* 2007;62(7):738-43.
18. Cesari M, Gambassi G, van Kan GA, Vellas B. The frailty phenotype and the frailty index: different instruments for different purposes. *Age Ageing.* 2014;43(1):10-2.
19. Theou O, Rockwood MR, Mitnitski A, Rockwood K. Disability and co-morbidity in relation to frailty: how much do they overlap? *Arch Gerontol Geriatr.* 2012;55(2):e1-8.
20. Wong CH, Weiss D, Sourial N, Karunanathan S, Quail JM, Wolfson C, et al. Frailty and its association with disability and comorbidity in a community-dwelling sample of seniors in Montreal: a cross-sectional study. *Aging Clin Exp Res.* 2010;22(1):54-62.
21. Vermeulen J, Neyens JC, van Rossum E, Spreuwenberg MD, de Witte LP. Predicting ADL disability in community-dwelling elderly people using physical frailty indicators: a systematic review. *BMC Geriatr.* 2011;11:33.
22. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. *J Am Geriatr Soc.* 2012;60(8):1487-92.
23. Kirkwood TB. Understanding the odd science of aging. *Cell.* 2005;120(4):437-47.
24. Lipsitz LA. Dynamics of stability: the physiologic basis of functional health and frailty. *J Gerontol A Biol Sci Med Sci.* 2002;57(3):B115-25.
25. Fried LP, Xue QL, Cappola AR, Ferrucci L, Chaves P, Varadhan R, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. *J Gerontol A Biol Sci Med Sci.* 2009;64(10):1049-57.
26. Abadir PM. The frail renin-angiotensin system. *Clin Geriatr Med.* 2011;27(1):53-65.
27. Afilalo J, Karunanathan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. *Am J Cardiol.* 2009;103(11):1616-21.
28. Chaves PH, Semba RD, Leng SX, Woodman RC, Ferrucci L, Guralnik JM, et al. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: the Women's Health and Aging Studies I and II. *J Gerontol A Biol Sci Med Sci.* 2005;60(6):729-35.
29. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. *Arch Intern Med.* 2002;162(20):2333-41.
30. Vaz Fragoso CA, Enright PL, McAvay G, Van Ness PH, Gill TM. Frailty and respiratory impairment in older persons. *Am J Med.* 2012;125(1):79-86.
31. Li H, Manwani B, Leng SX. Frailty, inflammation, and immunity. *Aging Dis.* 2011;2(6):466-73.
32. Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. *Clin Geriatr Med.* 2011;27(1):79-87.
33. Collerton J, Martin-Ruiz C, Davies K, Hilkens CM, Isaacs J, Kolenda C, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study. *Mech Ageing Dev.* 2012;133(6):456-66.
34. Hubbard RE, O'Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. *J Cell Mol Med.* 2009;13(9B):3103-9.
35. Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and frailty in older women. *J Am Geriatr Soc.* 2007;55(6):864-71.

36. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. *Clin Interv Aging*. 2014;9:433-41.
37. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. *J Gerontol A Biol Sci Med Sci*. 2002;57(5):M326-32.
38. Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. *J Am Geriatr Soc*. 2002;50(7):1268-71.
39. Leng SX, Hung W, Cappola AR, Yu Q, Xue QL, Fried LP. White blood cell counts, insulin-like growth factor-1 levels, and frailty in community-dwelling older women. *J Gerontol A Biol Sci Med Sci*. 2009;64(4):499-502.
40. Michelon E, Blaum C, Semba RD, Xue QL, Ricks MO, Fried LP. Vitamin and carotenoid status in older women: associations with the frailty syndrome. *J Gerontol A Biol Sci Med Sci*. 2006;61(6):600-7.
41. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing*. 2010;39(4):412-23.
42. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. *Current opinion in clinical nutrition and metabolic care*. 2012;15(1):12-22.
43. Jensen GL. Inflammation: roles in aging and sarcopenia. *JPEN Journal of parenteral and enteral nutrition*. 2008;32(6):656-9.
44. Clegg A, Young J. The frailty syndrome. *Clinical medicine (London, England)*. 2011;11(1):72-5.
45. Morley JE. Sarcopenia in the elderly. *Family practice*. 2012;29 Suppl 1:i44-i8.
46. Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. *Aging Clinical and Experimental Research*. 2004;16(2):153-7.
47. Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: The potential role of an aged immune system. *Ageing Res Rev*. 2017;36:1-10.
48. Ebisui C, Tsujinaka T, Morimoto T, Kan K, Iijima S, Yano M, et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. *Clinical science (London, England : 1979)*. 1995;89(4):431-9.
49. Franckhauser S, Elias I, Rotter Sopasakis V, Ferre T, Nagaev I, Andersson CX, et al. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. *Diabetologia*. 2008;51(7):1306-16.
50. Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. *The FEBS journal*. 2013;280(17):4294-314.
51. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. *Endocrine reviews*. 2004;25(5):831-66.
52. Morgan SA, Sherlock M, Gathercole LL, Lavery GG, Lenaghan C, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. *Diabetes*. 2009;58(11):2506-15.
53. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. *Am J Med*. 2006;119(6):526.e9-17.
54. Cesari M, Kritchevsky SB, Nicklas B, Kanaya AM, Patrignani P, Tacconelli S, et al. Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons:

- results from the health aging and body composition study. *J Gerontol A Biol Sci Med Sci.* 2012;67(6):671-6.
55. Ladner KJ, Caligiuri MA, Guttridge DC. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. *The Journal of biological chemistry.* 2003;278(4):2294-303.
56. Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF. Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology.* 2001;15(2):475-82.
57. Walston J, Fedarko N, Yang H, Leng S, Beamer B, Espinoza S, et al. The physical and biological characterization of a frail mouse model. *J Gerontol A Biol Sci Med Sci.* 2008;63(4):391-8.
58. Semba RD, Margolick JB, Leng S, Walston J, Ricks MO, Fried LP. T cell subsets and mortality in older community-dwelling women. *Experimental gerontology.* 2005;40(1-2):81-7.
59. Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. *Journal of acquired immune deficiency syndromes (1999).* 2009;50(3):299-306.
60. De Fanis U, Wang GC, Fedarko NS, Walston JD, Casolaro V, Leng SX. T-lymphocytes expressing CC chemokine receptor-5 are increased in frail older adults. *J Am Geriatr Soc.* 2008;56(5):904-8.
61. Leng SX, Yang H, Walston JD. Decreased cell proliferation and altered cytokine production in frail older adults. *Aging Clin Exp Res.* 2004;16(3):249-52.
62. Schmaltz HN, Fried LP, Xue QL, Walston J, Leng SX, Semba RD. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. *J Am Geriatr Soc.* 2005;53(5):747-54.
63. Leng SX, Xue QL, Tian J, Huang Y, Yeh SH, Fried LP. Associations of neutrophil and monocyte counts with frailty in community-dwelling disabled older women: results from the Women's Health and Aging Studies I. *Experimental gerontology.* 2009;44(8):511-6.
64. Qu T, Yang H, Walston JD, Fedarko NS, Leng SX. Upregulated monocytic expression of CXC chemokine ligand 10 (CXCL-10) and its relationship with serum interleukin-6 levels in the syndrome of frailty. *Cytokine.* 2009;46(3):319-24.
65. Qu T, Walston JD, Yang H, Fedarko NS, Xue QL, Beamer BA, et al. Upregulated ex vivo expression of stress-responsive inflammatory pathway genes by LPS-challenged CD14(+) monocytes in frail older adults. *Mech Ageing Dev.* 2009;130(3):161-6.
66. Hazeldine J, Lord JM. Innate immunosenescence: underlying mechanisms and clinical relevance. *Biogerontology.* 2015;16(2):187-201.
67. Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, et al. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. *Blood.* 2014;123(2):239-48.
68. Butcher SK, Chahal H, Nayak L, Sinclair A, Henriquez NV, Sapey E, et al. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans. *J Leukoc Biol.* 2001;70(6):881-6.
69. Hazeldine J, Harris P, Chapple IL, Grant M, Greenwood H, Livesey A, et al. Impaired neutrophil extracellular trap formation: a novel defect in the innate immune system of aged individuals. *Aging Cell.* 2014;13(4):690-8.
70. Brickson S, Ji LL, Schell K, Olabisi R, St Pierre Schneider B, Best TM. M1/70 attenuates blood-borne neutrophil oxidants, activation, and myofiber damage following stretch injury. *Journal of applied*

- physiology (Bethesda, Md : 1985). 2003;95(3):969-76.
71. Jolly SR, Kane WJ, Hook BG, Abrams GD, Kunkel SL, Lucchesi BR. Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. *American heart journal*. 1986;112(4):682-90.
72. Korthuis RJ, Grisham MB, Granger DN. Leukocyte depletion attenuates vascular injury in postischemic skeletal muscle. *The American journal of physiology*. 1988;254(5 Pt 2):H823-7.
73. Turner G, Clegg A, British Geriatrics S, Age UK, Royal College of General P. Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report. *Age Ageing*. 2014;43(6):744-7.
74. Ellis G, Whitehead MA, O'Neill D, Langhorne P, Robinson D. Comprehensive geriatric assessment for older adults admitted to hospital. *The Cochrane database of systematic reviews*. 2011(7):Cd006211.
75. Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. *J Am Geriatr Soc*. 1991;39(9 Pt 2):8S-16S; discussion 7S-8S.
76. Clegg AP, Barber SE, Young JB, Forster A, Iliffe SJ. Do home-based exercise interventions improve outcomes for frail older people? Findings from a systematic review. *Reviews in clinical gerontology*. 2012;22(1):68-78.
77. Theou O, Stathokostas L, Roland KP, Jakobi JM, Patterson C, Vandervoort AA, et al. The effectiveness of exercise interventions for the management of frailty: a systematic review. *Journal of aging research*. 2011;2011:569194.
78. Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Allore H, Byers A. A program to prevent functional decline in physically frail, elderly persons who live at home. *The New England journal of medicine*. 2002;347(14):1068-74.
79. Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. *The New England journal of medicine*. 1994;330(25):1769-75.
80. Allen S. Systemic Inflammation in the Genesis of Frailty and Sarcopenia: An Overview of the Preventative and Therapeutic Role of Exercise and the Potential for Drug Treatments. *Geriatrics*. 2017;2(1):6.
81. Forster A, Lambley R, Hardy J, Young J, Smith J, Green J, et al. Rehabilitation for older people in long-term care. *The Cochrane database of systematic reviews*. 2009(1):Cd004294.
82. de Vries NM, van Ravensberg CD, Hobbelen JS, Olde Rikkert MG, Staal JB, Nijhuis-van der Sanden MW. Effects of physical exercise therapy on mobility, physical functioning, physical activity and quality of life in community-dwelling older adults with impaired mobility, physical disability and/or multimorbidity: a meta-analysis. *Ageing Res Rev*. 2012;11(1):136-49.
83. Crocker T, Forster A, Young J, Brown L, Ozer S, Smith J, et al. Physical rehabilitation for older people in long-term care. *The Cochrane database of systematic reviews*. 2013(2):Cd004294.
84. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. *Journal of the American Medical Directors Association*. 2013;14(6):392-7.
85. Cawood AL, Elia M, Stratton RJ. Systematic review and meta-analysis of the effects of high protein oral nutritional supplements. *Ageing Res Rev*. 2012;11(2):278-96.
86. Tieland M, van de Rest O, Dirks ML, van der Zwaluw N, Mensink M, van Loon LJ, et al. Protein supplementation improves physical performance in frail elderly people: a randomized, double-blind,

- placebo-controlled trial. *Journal of the American Medical Directors Association*. 2012;13(8):720-6.
87. Malafarina V, Uriz-Otano F, Iñesta R, Gil-Guerrero L. Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review. *Journal of the American Medical Directors Association*. 2013;14(1):10-7.
88. Tieland M, Dirks ML, van der Zwaluw N, Verdijk LB, van de Rest O, de Groot LC, et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial. *Journal of the American Medical Directors Association*. 2012;13(8):713-9.
89. Puts MT, Visser M, Twisk JW, Deeg DJ, Lips P. Endocrine and inflammatory markers as predictors of frailty. *Clinical endocrinology*. 2005;63(4):403-11.
90. Murad MH, Elamin KB, Abu Elnour NO, Elamin MB, Alkatib AA, Fatourechi MM, et al. Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. *The Journal of clinical endocrinology and metabolism*. 2011;96(10):2997-3006.
91. Muir SW, Montero-Odasso M. Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis. *J Am Geriatr Soc*. 2011;59(12):2291-300.
92. Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, Sanders KM, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. *The Journal of clinical endocrinology and metabolism*. 2012;97(8):2670-81.
93. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, et al. Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial. *JAMA internal medicine*. 2016;176(2):175-83.
94. Cannell JJ, Grant WB, Holick MF. Vitamin D and inflammation. *Dermato-endocrinology*. 2014;6(1):e983401.
95. Guillot X, Semerano L, Saldenbergh-Kermanac'h N, Falgarone G, Boissier MC. Vitamin D and inflammation. *Joint, bone, spine : revue du rhumatisme*. 2010;77(6):552-7.
96. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. *Journal of immunology (Baltimore, Md : 1950)*. 2009;183(9):5458-67.
97. Yin K, Agrawal DK. Vitamin D and inflammatory diseases. *Journal of Inflammation Research*. 2014;7:69-87.
98. Calton EK, Keane KN, Newsholme P, Soares MJ. The Impact of Vitamin D Levels on Inflammatory Status: A Systematic Review of Immune Cell Studies. *PLOS ONE*. 2015;10(11):e0141770.
99. Hoe E, Nathanielsz J, Toh ZQ, Spry L, Marimla R, Balloch A, et al. Anti-Inflammatory Effects of Vitamin D on Human Immune Cells in the Context of Bacterial Infection. *Nutrients*. 2016;8(12).
100. Mousa A, Misso M, Teede H, Scragg R, de Courten B. Effect of vitamin D supplementation on inflammation: protocol for a systematic review. *BMJ Open*. 2016;6(4).
101. Schaufelberger M, Andersson G, Eriksson BO, Grimby G, Held P, Swedberg K. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. *European heart journal*. 1996;17(11):1678-85.
102. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older

- women: an observational study. *Lancet*. 2002;359 (9310):926-30.
103. Witham DMD. Leucine and ACEi to treat sarcopenia (LACE study) 2015. Available from: <https://www.ukctg.nihr.ac.uk/trials/trial-details/trial-details?trialId=15543>
104. Chang Y, Wei W. Angiotensin II in inflammation, immunity and rheumatoid arthritis. *Clinical and experimental immunology*. 2015;179(2):137-45.
105. Marketou ME, Zacharis EA, Koukouraki S, Stathaki MI, Arfanakis DA, Kochiadakis GE, et al. Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus. *Journal of human hypertension*. 2008;22(3):191-6.
106. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. *The New England journal of medicine*. 2010;363(2):109-22.
107. Friedlander AL, Butterfield GE, Moynihan S, Grillo J, Pollack M, Holloway L, et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. *The Journal of clinical endocrinology and metabolism*. 2001;86 (4):1496-503.